Carregant...

Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy

BACKGROUND: Point mutations of the BCR-ABL tyrosine kinase domain are considered the predominant cause of imatinib resistance in chronic myeloid leukemia. The expansion of mutant BCR-ABL-positive clones under selective pressure of tyrosine kinase inhibition is referred to as clonal selection; there...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Hanfstein, Benjamin, Müller, Martin C., Kreil, Sebastian, Ernst, Thomas, Schenk, Thomas, Lorentz, Christian, Schwindel, Uwe, Leitner, Armin, Hehlmann, Rüdiger, Hochhaus, Andreas
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2011
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3046266/
https://ncbi.nlm.nih.gov/pubmed/21134983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2010.030999
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!